细胞切片生物科学 突出癌症药物Iopofosine的成功, 计划进步 在生物技术展示。 Cellectar Biosciences highlights cancer drug iopofosine's success, plans advancements at Biotech Showcase.

Cellectar生物科学公司是一家生物制药公司,将在生物技术展示公司讨论其2025年战略举措,重点是癌症目标制剂Ioopofosine I 131。 Cellectar Biosciences, a biopharmaceutical firm, will discuss its 2025 strategic initiatives at the Biotech Showcase, focusing on iopofosine I 131, a cancer-targeting agent. 在第二阶段的一项研究中,iopofosine在重症复发/瓦尔登斯壮的宏观球体贫血方面达到83.6%的总体响应率。 In a Phase 2 study, iopofosine achieved an 83.6% overall response rate for relapsed/refractory Waldenstrom's macroglobulinemia. 该公司计划通过内部努力、伙伴关系和其他方法推进该药物,同时开发固体肿瘤的放射治疗资产。 The company plans to advance the drug through internal efforts, partnerships, and other methods, while also developing radiotherapeutic assets for solid tumors.